Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR0161)
Name
Methylprednisolone
Synonyms
methylprednisolone; 83-43-2; Medrol; Medrone; Metilprednisolone; Urbason; 6alpha-Methylprednisolone; Metilbetasone; Medrate; Dopomedrol; Promacortine; Besonia; Medesone; Mesopren; Metastab; Metrisone; Moderin; Noretona; Solomet; Urbasone; Wyacort; Methylprednisolon; Methyleneprednisolone; 6-alpha-Methylprednisolone; Metilprednisolone [DCIT]; delta(1)-6alpha-Methylhydrocortisone; 1-Dehydro-6alpha-methylhydrocortisone; Metilprednisolona; Methylprednisolonum; NSC-19987; Methylprednisolonum [INN-Latin]; Metilprednisolona [INN-Spanish]; Suprametil; Medrol dosepak; Medrol adt pak; 6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione; UNII-X4W7ZR7023; CHEBI:6888; (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione; (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; Prednisolone, methyl-; Methylprednisolone, 6-alpha; 11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione; 6alpha-Methylprednisolone base; U 7532; MLS000028541; (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; Sieropresol; Esametone; Firmacort; Medixon; Metrocort; Metysolon; Nirypan; Reactenol; Lemod; Artisone-wyeth; X4W7ZR7023; MEPRDL; Predni N Tablinen; Medlone 21; SMR000058330; Summicort;; 6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione; DSSTox_CID_3300; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6a,11b)-; Prednol- L; DSSTox_RID_76965; DSSTox_GSID_23300; Depo-Medrol (acetate); CAS-83-43-2; Prednisolone, 6alpha-methyl-; HSDB 3127; MLS002638721; EINECS 201-476-4; Prednisolone, 6.alpha.-methyl-; BRN 2340300; delta(sup 1)-6-alpha-Methylhydrocortisone; .DELTA.1-6.alpha.-Methylhydrocortisone; NCGC00016330-01; Prestwick_622; Medrol (TN); Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)-; 6?-Methylprednisolone; Methylprednisolone [USP:INN:BAN:JAN]; Opera_ID_1576; Prestwick0_000279; Prestwick1_000279; Prestwick2_000279; Prestwick3_000279; 6alpha-methyl prednisolone; 11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl-; CHEMBL650; EC 201-476-4; 6.alpha.-Methylprednisolone; SCHEMBL5084; BSPBio_000158; 4-08-00-03498 (Beilstein Handbook Reference); MLS001148159; MLS002207191; SPBio_002377; BPBio1_000174; GTPL7088; DTXSID7023300; HMS1568H20; HMS2090B13; HMS2095H20; HMS2230D16; HMS3259J04; HMS3712H20; 6alpha-Methylprednisolone, >=98%; HY-B0260; NSC19987; ZINC3875560; Tox21_110376; Tox21_302018; BDBM50103616; LMST02030178; Methylprednisolone (JP17/USP/INN); MFCD00010591; s1733; AKOS015969744; Pregna-1,4-diene-3,20-dione, 6-alpha-methyl-11-beta-17,21-trihydroxy-; Tox21_110376_1; ACN-037579; CCG-220279; DB00959; J3.872E; KS-1273; NC00691; NCGC00022735-03; NCGC00022735-06; NCGC00255269-01; H972; NCI60_001657; M1665; 2639-EP2277861A1; 2639-EP2286811A1; 2639-EP2292595A1; 2639-EP2295409A1; 2639-EP2298778A1; 2639-EP2305660A1; 2639-EP2308562A2; 2639-EP2314590A1; 2639-EP2371811A2; D00407; 010M591; 124684-EP2295426A1; 124684-EP2295427A1; Q417222; SR-01000003089; Q-201395; SR-01000003089-2; BRD-K35240538-001-03-1; BRD-K35240538-001-11-4; BRD-K35240538-001-26-2; 6-alpha-Methylprednisolone 100 microg/mL in Acetonitrile; 6alpha-Methylprednisolone, VETRANAL(TM), analytical standard; 11?,17?,21-Trihydroxy-6?-methyl-1,4-pregnadiene-3,20-dione; 11beta,17,21-trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione; Methylprednisolone, British Pharmacopoeia (BP) Reference Standard; Methylprednisolone, European Pharmacopoeia (EP) Reference Standard; Pregna-1,20-dione, 11.beta.,17,21-trihydroxy-6.alpha.-methyl-; Pregna-1,20-dione, 6.alpha.-methyl-11.beta.-17,21-trihydroxy-; (6?,11?)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; (6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione; 11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione; Methylprednisolone, United States Pharmacopeia (USP) Reference Standard; Methylprednisolone for system suitability A, EuropePharmacopoeia (EP) Reference Standard; Methylprednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard; Methylprednisolone, Pharmaceutical Secondary Standard; Certified Reference Material; Pregna-1,20-dione, 11,17,21-trihydroxy-6-methyl-, (6.alpha.,11.beta.)-; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6I+/-,11I(2))-; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
    Click to Show/Hide
Molecular Type
Small molecule
Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C22H30O5
PubChem CID
6741
Canonical SMILES
CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
InChI
1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
InChIKey
VHRSUDSXCMQTMA-PJHHCJLFSA-N
CAS Number
CAS 83-43-2
ChEBI ID
CHEBI:6888
TTD Drug ID
D08PIQ
DrugBank ID
DB00959
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Theophylline      Camellia sinensis     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Male Wistar Albino rats were used in this study.
                    Experimental
                    Result(s)
Combined use of theophylline and methylprednisolone had positive effects on the contraction strength and the durations of contraction and semi-relaxation of the diaphragm muscle.
Target and Pathway
Target(s) Glucocorticoid receptor (NR3C1)  Molecule Info  [3]
KEGG Pathway Neuroactive ligand-receptor interaction Click to Show/Hide
NetPath Pathway IL2 Signaling Pathway Click to Show/Hide
2 TCR Signaling Pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling Click to Show/Hide
2 Signaling events mediated by HDAC Class II
3 FOXA2 and FOXA3 transcription factor networks
4 Glucocorticoid receptor regulatory network
5 Regulation of Androgen receptor activity
6 AP-1 transcription factor network
Reactome BMAL1:CLOCK,NPAS2 activates circadian gene expression Click to Show/Hide
WikiPathways Serotonin Receptor 4/6/7 and NR3C Signaling Click to Show/Hide
2 SIDS Susceptibility Pathways
3 Nuclear Receptors Meta-Pathway
4 Endoderm Differentiation
5 Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
6 Adipogenesis
7 Circadian Clock
8 Nuclear Receptors
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Reference 2 Effects of Theophylline with Methylprednisolone Combination Therapy on Biomechanics and Histopathology in Diaphragm Muscles of Rats. Inflammation. 2016 Oct;39(5):1635-41.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China